409 related articles for article (PubMed ID: 20661235)
1. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update.
Maertens J; Marchetti O; Herbrecht R; Cornely OA; Flückiger U; Frêre P; Gachot B; Heinz WJ; Lass-Flörl C; Ribaud P; Thiebaut A; Cordonnier C;
Bone Marrow Transplant; 2011 May; 46(5):709-18. PubMed ID: 20661235
[TBL] [Abstract][Full Text] [Related]
2. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.
Tan BH; Low JG; Chlebicka NL; Kurup A; Cheah FK; Lin RT; Goh YT; Wong GC
Int J Infect Dis; 2011 May; 15(5):e350-6. PubMed ID: 21397541
[TBL] [Abstract][Full Text] [Related]
3. [Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi].
Salavert-Lletí M; Zaragoza-Crespo R
Rev Iberoam Micol; 2009 Mar; 26(1):81-9. PubMed ID: 19463284
[TBL] [Abstract][Full Text] [Related]
4. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.
Tissot F; Agrawal S; Pagano L; Petrikkos G; Groll AH; Skiada A; Lass-Flörl C; Calandra T; Viscoli C; Herbrecht R
Haematologica; 2017 Mar; 102(3):433-444. PubMed ID: 28011902
[TBL] [Abstract][Full Text] [Related]
5. Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients.
Shang W; Feng G; Sun R; Wang X; Liu W; Zhang S; Li J; Pang X; Wang Y; Zhang W
J Clin Pharm Ther; 2012 Dec; 37(6):652-6. PubMed ID: 22725946
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
7. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
[TBL] [Abstract][Full Text] [Related]
9. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
Salavert M; Jarque I
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
[TBL] [Abstract][Full Text] [Related]
10. Management of invasive mycoses in hematology patients: current approaches.
Perfect JR
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):5-14. PubMed ID: 15651177
[TBL] [Abstract][Full Text] [Related]
11. [Current indications for voriconazole in onco-hematological patients].
Jarque I; Sanz MA
Rev Iberoam Micol; 2007 Sep; 24(3):213-6. PubMed ID: 17874858
[TBL] [Abstract][Full Text] [Related]
12. New antifungal drugs and the pediatric cancer patient: current status of clinical development.
Groll AH; Lehrnbecher T
Klin Padiatr; 2005; 217(3):158-68. PubMed ID: 15858708
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
[TBL] [Abstract][Full Text] [Related]
14. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
[TBL] [Abstract][Full Text] [Related]
15. Echinocandins in the management of invasive fungal infections, Part 2.
Morris MI; Villmann M
Am J Health Syst Pharm; 2006 Oct; 63(19):1813-20. PubMed ID: 16990627
[TBL] [Abstract][Full Text] [Related]
16. New options for the treatment of invasive fungal infections.
Rubin ZA; Somani J
Semin Oncol; 2004 Apr; 31(2 Suppl 4):91-8. PubMed ID: 15124141
[TBL] [Abstract][Full Text] [Related]
17. Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients.
Steinbach WJ; Schell WA; Miller JL; Perfect JR; Martin PL
J Infect; 2004 Jan; 48(1):112-6. PubMed ID: 14667801
[No Abstract] [Full Text] [Related]
18. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]